MindBio Therapeutics Corp. Reports Six Month Sustained Antidepressant Response in Clinical Trials. 72% reduction in Depression Severity Recorded.Dear ,We are excited to share significant progress in our mission to transform mental health treatments....

Hi We are thrilled to share some significant progress from our ongoing Phase 2B clinical trial focused on advanced-stage cancer patients experiencing symptoms of anxiety, depression and existential distress. In this Phase 2B study, 40 participants ar...

Hi MindBio is pleased to report it has completed its 6-month milestone post treatment with MB22001 in a Phase 2A microdosing depression trial and will be releasing the data in the coming fortnight.Photo: Justin Hanka, MindBio CEO and Co-Founder insp...

Hi MindBio is pleased to report on long term stability data for its lead candidate drug MB22001. These stability findings, are an important part of our commercialisation journey, to produce medicines that can be stored and used safely for long perio...

Hi Join me as I discuss MindBio's landmark take-home microdosing clinical trial in patients with Major Depressive Disorder as we enter our 25th participant into this randomized, triple blind, double dummy, active placebo controlled trial.Click to Wat...

Hi I'm pleased to present a brief video update on whats happening at MindBio.We recently reported a sustained anti-depressant response from microdosing MB220001 at 1 months and 3 months post cessation of an 8-week treatment cycle. Our women's health...

Hi We continue take-home dosing in two Phase 2B clinical trials with a third Phase 2B women's health trial recently approved for use of a microdose of a psychedelic medicine (MB22001) to treat mood symptoms in Premenstrual Syndrome and Premenstrual D...

Hi Please see release from MindBio Therapeutics below.Vancouver, British Columbia – July 8, 2024 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a leading biopharmaceutical company in psychiatric microdosing me...

Hi We are pleased to present secondary data from MindBio's Phase 2A Microdosing Depression Trial completed earlier this year.Data from MindBio’s Phase 2A Depression trial indicates improvements in a range of secondary outcome measures following an 8-...

Hi Please see latest news release posted today from MindBio and Enveric Biosciences.Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders.M...